<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193189</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5379</org_study_id>
    <secondary_id>38569</secondary_id>
    <nct_id>NCT04193189</nct_id>
  </id_info>
  <brief_title>B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B</brief_title>
  <acronym>BEe-HIVe</acronym>
  <official_title>B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B
      in two study populations living with HIV: prior HBV vaccine recipients who are deemed
      non-responders and individuals who are naïve to HBV vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase III/IV study will evaluate the response to and safety of the HBV vaccine
      HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are
      deemed non-responders (Group A) and individuals who are naïve to HBV vaccination (Group B).

      Group A (HBV vaccine non-responders)

      The study is designed as an open-label three-arm study to evaluate whether:

        1. HEPLISAV-B vaccination given as a two-dose series achieves non-inferior seroprotection
           response (SPR) compared to standard dose ENGERIX-B.

        2. HEPLISAV-B vaccination given as a three-dose series achieves superior SPR proportion
           compared to standard dose ENGERIX-B.

      Participants are randomized in 1:1:1 ratio to the following study arms, stratified by sex at
      birth (male vs. female) and diabetes diagnosis status (yes vs. no):

        -  Arm 1: Two doses of HEPLISAV-B at weeks 0 and 4.

        -  Arm 2: Three doses of HEPLISAV-B at weeks 0, 4, and 24.

        -  Arm 3: Three doses of ENGERIX-B at weeks 0, 4, and 24.

      The target sample size in Group A is 561 participants, 187 participants in each arm.

      Group B (Naïve to HBV vaccination)

      Group B study is a single arm evaluation of vaccine response and safety of three doses of
      HEPLISAV-B. The target sample size is 73 participants.

      All participants will remain on their non-study-provided antiretroviral therapy (ART)
      throughout the study. Participants in both groups will attend several study visits through
      Week 72. Visits may include physical examinations and blood collection. For 7 days after each
      vaccination, participants will record temperature and any reactions they have to the vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 7, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection response defined as hepatitis B virus surface antibody (HBsAb) ≥10 mIU/mL</measure>
    <time_frame>Week 12 in Group A, Arm 1, Week 28 in Group A, Arms 2 and 3 and in Group B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Adverse events (AEs)</measure>
    <time_frame>From vaccination initiation to study discontinuation (Week 72 or premature discontinuation)</time_frame>
    <description>DAIDS AE Grading Table (Version 2.1) will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection response defined as HBsAb ≥10 mIU/mL</measure>
    <time_frame>Weeks 4, 8, 12, 24, 28, 32, 48, 52 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb titer</measure>
    <time_frame>Weeks 4, 8, 12, 24, 28, 32, 48, 52 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Grade ≥2 AEs within 4 weeks after each injection</measure>
    <time_frame>From vaccination initiation to Week 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">634</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A, Arm 1: HEPLISAV-B (two injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A, Arm 2: HEPLISAV-B (three injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A, Arm 3: ENGERIX-B (three injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: HEPLISAV-B (three injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV-B</intervention_name>
    <description>Administered by IM injection</description>
    <arm_group_label>Group A, Arm 1: HEPLISAV-B (two injections)</arm_group_label>
    <arm_group_label>Group A, Arm 2: HEPLISAV-B (three injections)</arm_group_label>
    <arm_group_label>Group B: HEPLISAV-B (three injections)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ENGERIX-B</intervention_name>
    <description>Administered by IM injection</description>
    <arm_group_label>Group A, Arm 3: ENGERIX-B (three injections)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria, Groups A and B

          -  HIV-1 infection

          -  On current HIV-1 antiretroviral therapy (ART)

          -  CD4+ T-cell count ≥100 cells/mm^3

          -  HIV-1 RNA &lt;1000 copies/mL

        Inclusion Criteria, Group A only

          -  Serum Hepatitis B antibody &lt;10 mlU/mL, non-reactive (negative), or indeterminate

          -  Documentation of HBV vaccination &gt;168 days prior to study entry

        Inclusion Criterion, Group B only

          -  Serum Hepatitis B antibody non-reactive (negative) within 45 days prior to study entry

        Exclusion Criteria, Groups A and B

          -  Infection or prior exposure to HBV

          -  Serum HBsAb level ≥10 mlU/mL or positive at screening or any other time prior to
             screening

          -  Presence of any active or acute AIDS-defining opportunistic infections

          -  Solid organ transplantation

          -  History of ascites, encephalopathy, or variceal hemorrhage

          -  Diagnosis of chronic kidney disease (CKD) stage G4

          -  Cancer diagnosis within 5 years

          -  Currently receiving chemotherapy

          -  Chronic use and/or receipt of systemically administered immunosuppressive

          -  Known allergy/sensitivity or any hypersensitivity to any HBV vaccine or yeast

          -  Active, serious infection other than HIV-1

          -  Receipt of any inactivated virus vaccine within 14 days

          -  Receipt of any of the following within 45 days prior to study entry:

               -  Live virus vaccine

               -  Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage
                  colony-stimulating factor (GM-CSF)

               -  Any other investigational medicinal agent

          -  Receipt of immunoglobulin or blood products within 90 days prior to study entry

          -  Receipt of an injection of DNA plasmids or oligonucleotides within 60 days prior to
             study entry

        Exclusion Criteria, Group A only

          -  Hepatitis B virus vaccination ≤168 days prior to study entry

          -  Receipt of HEPLISAV-B vaccine at any time prior to study entry

        Exclusion Criterion, Group B only

          -  Known HBV vaccination prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth E. Sherman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cincinnati CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen Marks, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Cornell Chelsea CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven Hendrickx, R.N.</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John Dwyer</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>353</phone_ext>
      <email>Jay.Dwyer@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Suzanne Fiorillo, M.S.P.H.</last_name>
      <phone>303-724-5931</phone>
      <email>suzanne.fiorillo@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Mall, R.N.</last_name>
      <phone>312-942-5865</phone>
      <email>mark_mall@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Theresa Flynn, R.N., M.S.N., A.N.P., B.S.N.</last_name>
      <phone>617-724-0072</phone>
      <email>tflynn@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael K. Klebert</last_name>
      <phone>314-747-1098</phone>
      <email>mklebert@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rondalya DeShields, R.N., B.S.N.</last_name>
      <phone>973-972-3729</phone>
      <email>deshierd@njms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Becky Straub, B.S.N., M.P.H., R.N.</last_name>
      <phone>919-843-9975</phone>
      <email>bstraub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Clinical Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sharon Kohrs, R.N., B.S.N.</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jane Baum, R.N.</last_name>
      <phone>216-844-2546</phone>
      <email>jb@clevelandactu.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathy Watson, B.S.N., R.N.</last_name>
      <phone>614-293-5856</phone>
      <email>kathy.watson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dawn R. Weinman</last_name>
      <phone>412-383-1748</phone>
      <email>drw38@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauren Rogers, CCRC</last_name>
      <phone>972-807-7370</phone>
      <email>lauren.rogers@aidsarms.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandra W. Cardoso, Ph.D., M.D.</last_name>
      <phone>55-21-22707064</phone>
      <email>sandra.wagner@ipec.fiocruz.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chennai Antiviral Research and Treatment (CART) CRS</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Faith E. Samson</last_name>
      <phone>91-44-39106811</phone>
      <email>beulah@cartcrs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre (TRC-ARC) CRS</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Parawee Thongpaeng</last_name>
      <phone>662-6523040</phone>
      <phone_ext>106</phone_ext>
      <email>parawee.t@hivnat.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>India</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom?
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses?
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available?
Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

